• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

为符合当前决策需求对肾癌患者TNM分期系统的更新：欧洲泌尿外科学会指南小组的提议

A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel.

作者信息

Capitanio Umberto, Bedke Jens, Albiges Laurence, Volpe Alessandro, Giles Rachel H, Hora Milan, Marconi Lorenzo, Klatte Tobias, Abu-Ghanem Yasmin, Dabestani Saeed, Fernández Pello Sergio, Hofmann Fabian, Kuusk Teele, Tahbaz Rana, Powles Thomas, Ljungberg Börje, Bex Axel

机构信息

Department of Urology, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS San Raffaele Hospital, Milan, Italy.

Department of Urology, University Hospital Tübingen, Tübingen, Germany; German Cancer Consortium and German Cancer Research Center, Heidelberg, Germany.

出版信息

Eur Urol. 2023 Jan;83(1):3-5. doi: 10.1016/j.eururo.2022.09.026. Epub 2022 Oct 15.

DOI:10.1016/j.eururo.2022.09.026
PMID:36253306
Abstract

Over the past decade, only minor changes have been introduced in the TNM staging system for renal cancer. Conversely, many milestones and modifications in management of the disease have been achieved, especially for patients with locally advanced and metastatic cancers. The European Association of Urology guidelines panel proposes a new TNM classification scheme for staging of renal cell carcinoma to reflect these breakthrough clinical improvements.

摘要

在过去十年中，肾癌的TNM分期系统仅做了一些微小改动。相反，在该疾病的治疗方面已取得了许多里程碑式进展和改进，尤其是对于局部晚期和转移性癌症患者。欧洲泌尿外科学会指南小组提出了一种新的肾细胞癌分期TNM分类方案，以反映这些突破性的临床进展。

相似文献

1
A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel.为符合当前决策需求对肾癌患者TNM分期系统的更新：欧洲泌尿外科学会指南小组的提议
Eur Urol. 2023 Jan;83(1):3-5. doi: 10.1016/j.eururo.2022.09.026. Epub 2022 Oct 15.
2
Re: Umberto Capitanio, Jens Bedke, Laurence Albiges, et al. A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2023;83:3-5.关于：翁贝托·卡皮塔尼奥、延斯·贝德克、劳伦斯·阿尔比热斯等。《肾癌患者TNM分期系统的更新以符合当前决策制定：欧洲泌尿外科学会指南小组的提议》。《欧洲泌尿外科杂志》。2023年；83卷：3 - 5页。
Eur Urol. 2023 Mar;83(3):e73. doi: 10.1016/j.eururo.2022.11.026. Epub 2022 Dec 14.
3
Reply to Yaxiong Tang, Xu Hu, Kan Wu, Yanxiang Shao, and Xiang Li's Letter to the Editor re: Umberto Capitanio, Jens Bedke, Laurence Albiges, et al. A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines Panel. Eur Urol. 2022;83:3-5.回复汤亚雄、胡旭、吴侃、邵艳祥及李响致编辑的信，信的内容关于：翁贝托·卡皮塔尼奥、延斯·贝德克、劳伦斯·阿尔比热斯等人。《更新肾癌患者TNM分期系统以符合当前决策：欧洲泌尿外科学会指南小组的提议》。《欧洲泌尿外科杂志》。2022年；83卷：第3 - 5页。
Eur Urol. 2023 Mar;83(3):e74-e75. doi: 10.1016/j.eururo.2022.12.001. Epub 2022 Dec 14.
4
Reassessing the current UICC/AJCC TNM staging for renal cell carcinoma.重新评估目前用于肾细胞癌的 UICC/AJCC TNM 分期系统。
Eur Urol. 2009 Oct;56(4):636-43. doi: 10.1016/j.eururo.2009.06.036. Epub 2009 Jul 7.
5
The current TNM staging system of renal cell carcinoma: are further improvements needed?肾细胞癌的现行TNM分期系统：是否需要进一步改进？
Arch Esp Urol. 2011 Dec;64(10):929-37.
6
Pathologic staging of renal cell carcinoma: significance of tumor classification with the 1997 TNM staging system.肾细胞癌的病理分期：1997年TNM分期系统对肿瘤分类的意义。
Cancer. 2001 Jan 15;91(2):354-61. doi: 10.1002/1097-0142(20010115)91:2<354::aid-cncr1009>3.0.co;2-9.
7
European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022: The Urologist's Point of View.欧洲泌尿外科协会肾细胞癌指南小组关于《2022年世界卫生组织肾脏肿瘤分类》的更新：泌尿外科医生的观点。
Eur Urol. 2023 Feb;83(2):97-100. doi: 10.1016/j.eururo.2022.11.001. Epub 2022 Nov 23.
8
International consultation on urologic diseases and the European Association of Urology international consultation on locally advanced renal cell carcinoma.国际泌尿疾病咨询会议和欧洲泌尿外科学会局部晚期肾细胞癌国际咨询会议。
Eur Urol. 2011 Oct;60(4):673-83. doi: 10.1016/j.eururo.2011.06.042. Epub 2011 Jun 29.
9
Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria.肾细胞癌的预后指标：采用修订的1997年TNM分期标准对643例患者进行的多因素分析
J Urol. 2000 Apr;163(4):1090-5; quiz 1295. doi: 10.1016/s0022-5347(05)67699-9.
10
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update.欧洲泌尿外科学会肾癌指南：2022 年更新版。
Eur Urol. 2022 Oct;82(4):399-410. doi: 10.1016/j.eururo.2022.03.006. Epub 2022 Mar 26.

引用本文的文献

1
Reassessment of T1a cutoff for kidney cancer in the robotic era.机器人时代肾癌T1a临界值的重新评估。
J Robot Surg. 2025 Sep 12;19(1):595. doi: 10.1007/s11701-025-02775-7.
2
Evaluation of the Expression of IDO and PTEN in Human Kidney Cancer.人肾癌中吲哚胺 2,3-双加氧酶（IDO）和第 10 号染色体缺失的磷酸酶及张力蛋白同源物（PTEN）表达的评估
Curr Issues Mol Biol. 2025 May 13;47(5):359. doi: 10.3390/cimb47050359.
3
Current use of percutaneous ablation in renal tumors: an analysis of the registry of the German Society for Interventional Radiology and Minimally Invasive Therapy.
经皮消融术在肾肿瘤中的当前应用：德国介入放射学和微创治疗学会登记处的分析
Eur Radiol. 2025 Mar;35(3):1723-1731. doi: 10.1007/s00330-024-11343-w. Epub 2025 Feb 28.
4
Can multiparametric MRI clear cell likelihood scores differentiate fat-Poor AML from CcRCC in subcentimeter lesions?多参数MRI透明细胞可能性评分能否区分亚厘米级病变中的乏脂性AML和肾透明细胞癌？
Abdom Radiol (NY). 2025 Feb 5. doi: 10.1007/s00261-025-04822-1.
5
Can We Predict the Grade of Clear Cell Renal Cell Carcinoma from Houns-Field Unit of Renal Lesion on Computerized Tomography Scan, a Retrospective Cross-Sectional Study.我们能否通过计算机断层扫描中肾脏病变的亨氏单位预测透明细胞肾细胞癌的分级：一项回顾性横断面研究
Int J Gen Med. 2024 Apr 23;17:1571-1577. doi: 10.2147/IJGM.S452754. eCollection 2024.
6
Predicting Recurrence After Radical Surgery for High-Risk Renal Cell Carcinoma: Development and Internal Validation of the "TOWARDS" Score.高危肾细胞癌根治性手术后复发的预测：“迈向”评分的建立与内部验证。
Ann Surg Oncol. 2024 May;31(5):3513-3522. doi: 10.1245/s10434-024-14963-0. Epub 2024 Jan 29.
7
Establishment and validation of a nomogram to select patients with metastatic sarcomatoid renal cell carcinoma suitable for cytoreductive radical nephrectomy.用于选择适合减瘤性根治性肾切除术的转移性肉瘤样肾细胞癌患者的列线图的建立与验证
Front Oncol. 2023 Oct 23;13:1239405. doi: 10.3389/fonc.2023.1239405. eCollection 2023.
8
The Role of the Cardiac Biomarkers in the Renal Cell Carcinoma Multidisciplinary Management.心脏生物标志物在肾细胞癌多学科管理中的作用
Diagnostics (Basel). 2023 May 30;13(11):1912. doi: 10.3390/diagnostics13111912.
9
Cuproptosis identifies respiratory subtype of renal cancer that confers favorable prognosis.铜死亡鉴定出具有良好预后的肾癌呼吸亚型。
Apoptosis. 2022 Dec;27(11-12):1004-1014. doi: 10.1007/s10495-022-01769-2. Epub 2022 Sep 14.